1
|
Ioannou XP, Griebel P, Hecker R, Babiuk LA, van Drunen Littel-van den Hurk S. The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J Virol 2002; 76:9002-10. [PMID: 12186884 PMCID: PMC136463 DOI: 10.1128/jvi.76.18.9002-9010.2002] [Citation(s) in RCA: 99] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2002] [Accepted: 06/11/2002] [Indexed: 11/20/2022] Open
Abstract
The immunogenicity and protective efficacy of a bovine herpesvirus 1 (BHV-1) subunit vaccine formulated with Emulsigen (Em) and a synthetic oligodeoxynucleotide containing unmethylated CpG dinucleotides (CpG ODN) was determined in cattle. A truncated, secreted version of BHV-1 glycoprotein D (tgD) formulated with Em and CpG ODN at concentrations of 25, 2.5, or 0.25 mg/dose produced a more balanced immune response, higher levels of virus neutralizing antibodies, and greater protection after BHV-1 challenge compared to tgD adjuvanted with either Em or CpG ODN alone. In contrast, tgD formulated with Em and either 25 mg of a non-CpG ODN or another immunostimulatory compound, dimethyl dioctadecyl ammonium bromide, induced similar immunity and protection compared to tgD formulated with Em alone, a finding which confirms the immunostimulatory effect of ODN to be CpG motif mediated. Our results demonstrate the ability of CpG ODN to induce a strong and balanced immune response in a target species.
Collapse
Affiliation(s)
- X P Ioannou
- Veterinary Infectious Disease Organization, Saskatoon, Saskatchewan, S7N 5E3 Canada
| | | | | | | | | |
Collapse
|
2
|
Abstract
Intradermal (ID) inoculation has been investigated as a means of vaccinating laboratory animals, domestic farm animals, and humans. Various forms of viral, bacterial, parasitic, and fungal antigens have been administered ID, with varying results. This review emphasizes results from studies reporting clinically relevant outcomes such as clinical protection and body weight change following experimental challenge. Antibody titers, cytokines, cellular responses are included as supportive data. Based on the reports reviewed, ID vaccination is a promising alternative to more traditional routes of vaccination. ID vaccination has particular appeal to the beef cattle industry based on recently emphasized quality assurance issues. It is evident that the ultimate test of vaccine efficacy is the ability to protect against clinical disease under natural challenge conditions. We propose that the immune response of ID vaccinated cattle, using clinically relevant outcomes such as morbidity, mortality, average daily gain and feed efficiency, needs to be further investigated to define the value of this potentially effective and practical means of antigen delivery, particularly for domesticated farm animals.
Collapse
Affiliation(s)
- B D Hunsaker
- Schering-Plough Animal Health, Rt. 1 Box 68, Claude, TX 79019, USA.
| | | |
Collapse
|
3
|
|
4
|
Galeota JA, Flores EF, Kit S, Kit M, Osorio FA. A quantitative study of the efficacy of a deletion mutant bovine herpesvirus-1 differential vaccine in reducing the establishment of latency by wildtype virus. Vaccine 1997; 15:123-8. [PMID: 9066027 DOI: 10.1016/s0264-410x(96)00165-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Using quantitative polymerase chain reaction (PCR) we have studied the latency established by wildtype (WT) bovine herpesvirus-1 (BHV-1) after challenge of cattle that had been vaccinated with a double deletion (gC-/tk-) mutant BHV-1 vaccine. Fourteen animals were vaccinated intramuscularly with 2 ml containing 10(7.4) CCID50 (cell culture infectious dose 50%) of IBRV (NG) dltkdlgC and challenged, along with six unvaccinated control animals, 30 days later with 10(8.2) CCID50 of WT BHV-1 (Cooper). The ability of this vaccine to prevent acute clinical BHV-1 infection after this challenge has been previously reported. Sixty days after challenge, eight of the vaccinates and the six control animals were euthanitized and the trigeminal ganglia (TG) examined for the amount of WT BHV-1 DNA by an internal standard quantitative PCR. The quantitative protocol that we used is based on co-amplification of BHV-1 gC specific sequences (present in WT BHV-1 but absent in the vaccine strain) and sequences from the bovine growth hormone (BGH) gene, which is used as an internal standard. The TG of the eight vaccinates contained BHV-1 WT DNA, but in a statistically significantly lower amount than the unvaccinated controls. These results are significant from the standpoint that, to our knowledge, this is the first report of a systematic quantitative approach to the study of the effect of BHV-1 vaccines on latency. This technique could be used to measure and compare the efficiency of various BHV-1 vaccines in preventing or diminishing latency, which is a significant factor for the perpetuation of BHV-1 in cattle populations.
Collapse
Affiliation(s)
- J A Galeota
- Department of Veterinary and Biomedical Sciences, University of Nebraska, Lincoln 68583-0905, USA
| | | | | | | | | |
Collapse
|
5
|
Gao Y, Leary TP, Eskra L, Splitter GA. Truncated bovine herpesvirus-1 glycoprotein I (gpI) initiates a protective local immune response in its natural host. Vaccine 1994; 12:145-52. [PMID: 8147097 DOI: 10.1016/0264-410x(94)90053-1] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Current modified live and killed BHV-1 vaccines have not reduced the incidence of bovine herpesvirus-1 (BHV-1), the principal viral agent in bovine respiratory disease complex. The requirement for production of viral proteins for immune study has resulted in the establishment of a cell line which constitutively expresses BHV-1 gpI. A truncated BHV-1 envelope gpI protein was secreted into the culture supernatant of D17 cells transfected with the gpI gene lacking the coding sequence for the transmembrane region (TMR). The transmembrane domain is essential for gpI stability in the envelope, virus infectivity and, most probably, natural killer cell recognition; however, we have tested the possibility that this domain is not required for inducing an adaptive, protective immune response. Immunization of calves with this truncated gpI protein induced gpI-specific nasal IgA, IgG1, serum neutralizing antibodies and gpI-specific peripheral lymphocyte proliferation. All immunized calves were protected from clinical disease after BHV-1 challenge. Further, nine of ten immunized calves had no intranasal viral shedding. One animal shed a minimal amount of virus following challenge, but produced no antibodies to other viral proteins as evidenced by immunoprecipitation of 35S-labelled viral proteins by sera from virus-challenged animals. This study represents the first evidence that a recombinant truncated gpI subunit vaccine can confer local mucosal immunity and establish a strong protective barrier against disease caused by BHV-1 in the natural host. Also, these data demonstrate the feasibility of preventing initial viral replication in the host and distinguishing vaccinated from wild-type virus-infected animals.
Collapse
Affiliation(s)
- Y Gao
- Department of Animal Health and Biomedical Sciences, University of Wisconsin-Madison 53706
| | | | | | | |
Collapse
|
6
|
van Drunen Littel-van den Hurk S, Tikoo SK, Liang X, Babiuk LA. Bovine herpesvirus-1 vaccines. Immunol Cell Biol 1993; 71 ( Pt 5):405-20. [PMID: 8270270 DOI: 10.1038/icb.1993.47] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Vaccination has been important in controlling a wide variety of viral and bacterial infections of man and animals. Vaccines to herpesvirus infection of cattle are no exception. The present review describes the different types of conventional vaccines that have been used to date and furthermore describes the novel approaches which are presently being implemented to develop more effective vaccines. These include subunit vaccines as well as genetically engineered modified live deletion mutants. Both these novel vaccine approaches appear to be more efficacious than conventional vaccines. Furthermore, these vaccines provide an additional dimension for control and eradication of infection by providing an opportunity to develop companion diagnostic tests to differentiate infected animals from vaccinated animals. This review summarizes these developments as well as present knowledge regarding the important host defence mechanisms required for preventing infection and aiding recovery from infection.
Collapse
|
7
|
Abstract
A description of new commercial and experimental vaccines for viral and bacterial diseases of cattle can be broadly divided into those used for both beef and dairy cows and those used predominantly in dairy cattle. For both types of cattle, newer and experimental vaccines are directed against several of the important viral (e.g., bovine herpesvirus 1, bovine viral diarrhea virus, bovine respiratory syncytial virus, parainfluenza type 3, and foot-and-mouth disease virus) and bacterial pathogens (e.g., Pasteurella spp., Haemophilus somnus). The viral vaccines include gene-deleted, modified live, subunit, and peptide antigens. Newer bacterial vaccines, particularly those for Pasteurella spp., are composed of either modified-live vaccines or bacterins supplemented with toxoid or surface antigens. Haemophilus somnus vaccine research has concentrated mainly on defining unique surface antigens. Novel dairy cow vaccines would include the lipopolysaccharide-core (J5) antigen approach, which has been used for successful immunization against coliform mastitis. Core antigen vaccines also have reduced calf mortality from Gram-negative pathogens. Staphylococcal mastitis vaccines that contain capsular antigens, toxoids, or the staphylococcal fibronectin receptor are of active research interest. Vaccines against mastitis induced by Streptococcus agalactiae and Streptococcus uberis also are areas of intensive research. Delivery of multiple subunit antigens with optimal immune response induction has led to the investigation of attenuated heterologous viral and bacterial expression vectors such as bovine herpesvirus 1, vaccinia, and Salmonella spp. This discussion also demonstrates that molecular biology is being used to advance bovine vaccine technology.
Collapse
Affiliation(s)
- R J Yancey
- Animal Health Therapeutics Research, Upjohn Company, Kalamazoo, MI 49001
| |
Collapse
|
8
|
Baranowski E, Dubuisson J, Pastoret PP, Thiry E. Identification of 108K, 93K, and 42K glycoproteins of bovine herpesvirus-1 by monoclonal antibodies. Arch Virol 1993; 133:97-111. [PMID: 8240021 DOI: 10.1007/bf01309747] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Three glycoproteins of bovine herpesvirus-1 (BHV-1) other than glycoproteins gI, gIII, and gIV were identified by monoclonal antibody (MAb) analyses. Monoclonal antibodies were obtained by immunization of mice with either BHV-1 envelope or virus infected cells, from which the glycoproteins gI, gIII, and gIV were removed by immunoaffinity. In the latter immunization procedure mice were tolerized either against normal cellular antigens with or without glycoproteins gI, gIII, gIV, and nucleocapsid. From 154 anti-BHV-1 hybridomas isolated, 39 MAbs precipitated a 108K glycoprotein. Two other glycoproteins of respectively 42K and 93K were precipitated each by one MAb. These three glycoproteins were detected in infected cell lysate. Nine anti-108K glycoprotein MAbs neutralized BHV-1 infectivity and three non-neutralizing MAbs were able to reduce plaque development when virus was grown in the presence of these MAbs. It is therefore suggested that this glycoprotein is involved in viral entry into the cell and in cell-to-cell spread of the virus.
Collapse
Affiliation(s)
- E Baranowski
- Department of Virology-Immunology, Faculty of Veterinary Medicine, University of Liège, Belgium
| | | | | | | |
Collapse
|
9
|
Abstract
Four foals were raised under specific pathogen free (SPF) conditions. At 3 to 4 months of age, SPF foals and 1 other non-SPF foal were intranasally inoculated with equine herpes virus type 1 (EHV-1). Clinical signs included depression, fever, inappetence and intermittent coughing. Clinical recovery was complete by seven days but high titres of virus were detected in nasal mucus for at least 10 days after inoculation. Clinical illness was less severe in the non-SPF foal. Interferon was detected in the nasal mucus of all foals from 2 days post infection (dpi), persisting until 8 or 10 dpi. ELISA antibody was detected in serum from 6 dpi. Titres continued to rise throughout the period of observation, and were slightly stimulated by re-inoculation. EHV antibody, identified as belonging to the IgM class by the double sandwich ELISA, was detected from 6 dpi. Peak IgM titres were observed between day 10 and 18, declining to base levels by day 42. Virus neutralizing antibody was detectable in serum from day 14 and rises in titre were parallel to that of total ELISA antibody. Cellular immunity in EHV-1 infected SPF horses was examined by the antibody dependent cytotoxicity (ADCC) test and the specific lymphocyte transformation test. The ability of foal neutrophils to effect ADCC decreased significantly between 3 to 10 days after inoculation. Peripheral blood mononuclear cells (PBMC) displayed reactivity towards EHV-1 antigens from about day 14, with maximum stimulation indices being obtained between 28 and 42 dpi.
Collapse
Affiliation(s)
- Y C Chong
- Department of Clinical Veterinary Medicine, Cambridge, UK
| | | |
Collapse
|
10
|
Israel BA, Herber R, Gao Y, Letchworth GJ. Induction of a mucosal barrier to bovine herpesvirus 1 replication in cattle. Virology 1992; 188:256-64. [PMID: 1314454 DOI: 10.1016/0042-6822(92)90755-e] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Current vaccines for human and animal herpesviruses engender an immunity that may ameliorate disease but generally fails to prevent infection, latency, reactivation from latency, or spread through a population. By administering intranasally to cattle bovine herpesvirus type 1 virion envelope proteins combined with the potent mucosal immune system adjuvant, cholera toxin B subunit, we engendered a local antibody response that acted as a barrier to infection of mucosal epithelial cells and thereby prevented viral replication, consequently precluding disease, latency, and spread.
Collapse
Affiliation(s)
- B A Israel
- Department of Veterinary Science, Unversity of Wisconsin, Madison, 53706
| | | | | | | |
Collapse
|
11
|
York JJ, Fahey KJ. Vaccination with affinity‐purified glycoproteins protects chickens against infectious laryngotracheitis herpesvirus. Avian Pathol 1991; 20:693-704. [DOI: 10.1080/03079459108418808] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
12
|
Hutchings DL, van Drunen Littel-van den Hurk S, Babiuk LA. Lymphocyte proliferative responses to separated bovine herpesvirus 1 proteins in immune cattle. J Virol 1990; 64:5114-22. [PMID: 2168990 PMCID: PMC248003 DOI: 10.1128/jvi.64.10.5114-5122.1990] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
The immune response to bovine herpesvirus 1 (BHV-1) infection can protect cattle from subsequent challenge with the virus. This protection involves a variety of defensive strategies, and the activation of most of these defenses requires the recognition of viral proteins by the cellular immune system. To identify some of the BHV-1 proteins recognized by T lymphocytes, we measured in vitro proliferative responses to individual proteins. Viral proteins were separated by gel electrophoresis followed by Western immunoblotting, and immunoblots were evaluated for serological reactions. Unstained blotted fractions were processed into antigen-bearing particles for analysis in blastogenesis assays. Purified BHV-1 proteins obtained by immunoadsorbent chromatography were processed and included for comparison in both enzyme-linked immunosorbent and proliferation assays. The tegument protein VP8 and the glycoprotein gIV appeared to be the antigens which most consistently stimulated the proliferation of lymphocytes from BHV-1-immunized animals. Positive blastogenic responses were also detected to gI, gIII, and to one or more uncharacterized, low-molecular-weight proteins in some of the cattle tested. These results indicate that T-lymphocyte proliferative responses to BHV-1 proteins are detectable in immune cattle and may be important in protection from BHV-1 infection.
Collapse
Affiliation(s)
- D L Hutchings
- Agriculture Canada, Health of Animals Laboratory, Saskatoon, Saskatchewan
| | | | | |
Collapse
|
13
|
van Drunen Littel-van den Hurk S, Gifford GA, Babiuk LA. Epitope specificity of the protective immune response induced by individual bovine herpesvirus-1 glycoproteins. Vaccine 1990; 8:358-68. [PMID: 1697722 DOI: 10.1016/0264-410x(90)90095-4] [Citation(s) in RCA: 62] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Affinity-purified bovine herpesvirus-1 (BHV-1) glycoproteins gI, gIII and gIV, as well as a virus-free BHV-1-infected cell lysate were injected intramuscularly into seronegative calves. All immunized animals developed specific serum-neutralizing antibodies and they were fully protected from disease, using a BHV-1/Pasteurella haemolytica challenge model. After challenge, viral replication in the nasal passages was significantly reduced in animals vaccinated with gIV (10,000-fold) or BHV-1-infected cell lysate (450,000-fold) but just slightly reduced in animals immunized with gI (500-fold) or gIII (25-fold). All of the known epitopes of the glycoproteins were retained during the affinity-purification or preparation of the cell lysate. The high level of protection induced by gIV and the virus-infected cell lysate in particular indicates the potential of glycoprotein gIV as a subunit vaccine, ideally in combination with component(s) from the cell lysate, which may mediate cellular immune responses.
Collapse
|
14
|
Noel EJ, Israel BA, Letchworth GJ, Czuprynski CJ. Effects of immunization with bovine herpesvirus-1 glycoproteins on bovine herpesvirus-1-induced alteration of bovine neutrophil chemotactic and anti-Pasteurella haemolytica activities. Vaccine 1988; 6:433-9. [PMID: 2848379 DOI: 10.1016/0264-410x(88)90145-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
It has been reported previously that active bovine herpesvirus-1 (BHV-1) infection greatly enhances the susceptibility of cattle to secondary bacterial pneumonia involving Pasteurella haemolytica. The present study examines the possibility that immunization of BHV-1 naive calves with purified BHV-1 glycoproteins would protect them against changes in neutrophil function that might compromise their ability to eliminate P. haemolytica during an active BHV-1 infection. The results show that circulating neutrophil chemotactic activity was generally reduced at 7-8 days after BHV-1 challenge; immunization with a 77 kilodalton BHV-1 glycoprotein (gIV) prevented impairment of neutrophil chemotaxis. BHV-1 infection did not markedly affect the ability of neutrophils to ingest and kill P. haemolytica in vitro. Immunization and challenge with BHV-1 had little effect on the chemiluminescence response of bovine neutrophils to opsonized P. haemolytica in vitro, although in one experiment a marked increase in baseline neutrophil chemiluminescence was observed which may be relevant to understanding the pathogenesis of pulmonary damage that occurs in BHV-1 infected calves.
Collapse
Affiliation(s)
- E J Noel
- Department of Pathobiological Sciences, School of Veterinary Medicine, Madison, WI 53706
| | | | | | | |
Collapse
|
15
|
Marshall RL, Letchworth GJ. Passively administered neutralizing monoclonal antibodies do not protect calves against bovine herpesvirus 1 infection. Vaccine 1988; 6:343-8. [PMID: 2461005 DOI: 10.1016/0264-410x(88)90181-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Monoclonal antibodies specific for defined epitopes on the gI, gIII and gIV envelope glycoproteins of BHV-1 were used individually or in glycoprotein-monospecific pools for passive immunization of young calves. Although serum antibody titres comparable to those found in naturally infected and recovered calves were achieved, passive immunization failed to prevent the growth of BHV-1 in nasal and ocular mucosa and did not decrease the duration of viral shedding.
Collapse
Affiliation(s)
- R L Marshall
- Department of Veterinary Science, University of Wisconsin-Madison 53706
| | | |
Collapse
|
16
|
Expression and affinity purification of recombinant bovine herpes virus-1 glycoproteins. ACTA ACUST UNITED AC 1988. [DOI: 10.1007/bf01404136] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|